IL12A
ENSG00000168811
Target class
Secreted protein
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- IL12A
- Gene name
- Interleukin 12A
- Gene symbol
- IL12A
- Previous gene symbols
- NKSF1
- Protein name
- Interleukin-12 subunit alpha (IL-12A) (Cytotoxic lymphocyte maturation factor 35 kDa subunit) (CLMF p35) (IL-12 subunit p35) (NK cell stimulatory factor chain 1) (NKSF1)
- CLMF
- IL-12A
- p35
- NFSK
- Gene biotype
- Protein coding
- Gene family
- Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 23
- Highest tissue expression
- 7.36
- Tissue specificity (Gini)
- 0.482
- Tissue specificity (tau)
- 0.859
- KEGG gene identifiers
- hsa:3592
- Protein interaction confidence
- 0.791059
- Protein interaction partners
- 17
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-8984722
- R-HSA-9020591
- End position
- 159996019
- Start position
- 159988835
- Chromosome
- 3
- Strand
- Forward
- Secreted .
- PubMed 1674604
- PubMed 9342359
- Tissue specificity (tau)
- 0.858926
- Expression inequality (Gini)
- 0.481781
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 7.36
- Esophagus - Mucosa
- 6.58
- Spleen
- 3.48
- Lung
- 2.93
- Cells - Cultured fibroblasts
- 2.9
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes7.36
- Esophagus - Mucosa6.58
- Spleen3.48
- Lung2.93
- Cells - Cultured fibroblasts2.9
- Small Intestine - Terminal Ileum1.91
- Brain - Substantia nigra1.73
- Colon - Sigmoid1.61
- Brain - Amygdala1.55
- Brain - Hippocampus1.42
- Brain - Putamen (basal ganglia)1.38
- Brain - Hypothalamus1.32
- Brain - Spinal cord (cervical c-1)1.32
- Fallopian Tube1.31
- Brain - Anterior cingulate cortex (BA24)1.28
- Colon - Transverse1.26
- Brain - Frontal Cortex (BA9)1.24
- Brain - Cortex1.2
- Brain - Nucleus accumbens (basal ganglia)1.16
- Testis1.09
- Pituitary1.09
- Vagina1.07
- Brain - Caudate (basal ganglia)1.07
- Esophagus - Muscularis0.97
- Esophagus - Gastroesophageal Junction0.94
And 29 more, listed on the interactive page.
- GO:0001916
- GO:0002860
- GO:0006955
- GO:0009615
- GO:0010224
- GO:0016477
- GO:0032496
- GO:0032700
- GO:0032729
- GO:0032816
- GO:0032946
- GO:0034393
- GO:0035722
- GO:0042531
- GO:0045785
- GO:0045954
- GO:0048662
- GO:0050671
- GO:0050709
- GO:0050830
- GO:0051135
- GO:0097191
- GO:0098586
- GO:1900747
- GO:1903588
And 1 more, listed on the interactive page.
- GO:0005576
- GO:0005788
- GO:0031906
- GO:0043514
- GO:0005125
- GO:0005515
- GO:0008083
- GO:0042163
- GO:0045513
- GO:0046982
Related records
Trials (248)
- A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis
- A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
- A Long-term Extension Study of Ustekinumab in Pediatric Participants
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
- A Multicentered Prospective Cohort Study of Chinese IBD Patients
- A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers
- A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
- A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
- A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
- A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
- A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers
- A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa
- A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
- A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
- A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
- A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
- A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
- A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
Drugs (3)
- Briakinumab Interleukin-12 inhibitor
- Ebdarokimab Interleukin-12 inhibitor
- Ustekinumab Interleukin-12 inhibitor